Michelle Le Beau Net Worth

The estimated Net Worth of Beau Michelle Le is at least $22 Tisíc dollars as of 16 February 2021. Michelle Le owns over 1,333 units of Varian Medical Systems stock worth over $22,041 and over the last 5 years he sold VAR stock worth over $0. In addition, he makes $0 as Independent Director at Varian Medical Systems.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Michelle Beau VAR stock SEC Form 4 insiders trading

Michelle has made over 1 trades of the Varian Medical Systems stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 1,333 units of VAR stock worth $22,041 on 16 February 2021.

The largest trade he's ever made was exercising 1,333 units of Varian Medical Systems stock on 16 February 2021 worth over $22,041. On average, Michelle trades about 333 units every 0 days since 2020. As of 16 February 2021 he still owns at least 1,333 units of Varian Medical Systems stock.

You can see the complete history of Michelle Le stock trades at the bottom of the page.

Michelle Le Beau biography

Dr. Michelle Le Beau Ph.D. serves as Independent Director of the Company. ositions at the University of Chicago: • ?Arthur and Marian Edelstein Professor of Medicine, Section of Hematology/Oncology (1986—present) • ?Director, University of Chicago Medicine Comprehensive Cancer Center (2004—present) • ?Board Member of the University of Chicago Medicine Cancer Council (2012—present) • ?Director, Cancer Cytogenetics Laboratory (1986—present)

How old is Michelle Beau?

Michelle Beau is 65, he's been the Independent Director of Varian Medical Systems since 2019. There are 1 older and 12 younger executives at Varian Medical Systems. The oldest executive at Varian Medical Systems, Inc. is David Illingworth, 66, who is the Independent Director.

What's Michelle Beau's mailing address?

Beau's mailing address filed with the SEC is C/O VARIAN MEDICAL SYSTEMS, INC., 3100 HANSEN WAY, MAIL STOP E-327, PALO ALTO, CA, 94304.

Insiders trading at Varian Medical Systems

Over the last 22 years, insiders at Varian Medical Systems have traded over $57,574,967 worth of Varian Medical Systems stock and bought 500 units worth $22,595 . The most active insiders traders include Kent J Thiry, Timothy E Guertin a Dow R Wilson. On average, Varian Medical Systems executives and independent directors trade stock every 11 days with the average trade being worth of $181,124. The most recent stock trade was executed by Jesse Michael Bruff on 1 March 2021, trading 6,499 units of VAR stock currently worth $1,142,589.

What does Varian Medical Systems do?

Complete history of Michelle Le stock trades at Varian Medical Systems

Varian Medical Systems executives and stock owners

Varian Medical Systems executives and other stock owners filed with the SEC include:

• Dow Wilson,
  Chief Executive Officer, Director
• Kolleen Kennedy,
  President - Proton Solutions Division and Chief Growth Officer
• Chris Toth,
  President, Chief Operating Officer
• R. Andrew Eckert,
  Independent Chairman of the Board
• Jeffrey Balser,
  Independent Director
• Judy Bruner,
  Independent Director
• Anat Ashkenazi,
  Independent Director
• Jean-Luc Butel,
  Independent Director
• Regina Dugan,
  Independent Director
• David Illingworth,
  Independent Director
• Phillip Febbo,
  Independent Director
• Michael Hutchinson,
  Senior Vice President, Chief Legal Officer
• Francis Facchini,
  President, Interventional Solutions Business
• Anshul Maheshwari,
  Vice President, Treasurer and Investor Relations
• Michelle Le Beau,
  Independent Director
• J. Michael Bruff,
  Chief Financial Officer, Senior Vice President - Finance
• Magnus Momsen,
  SVP, CAO, Corporate Controller
• Mark R Laret,
  Director
• Jose Baselga,
  Director
• John W Kuo,
  SVP, Gen Counsel and Secretary
• Gary E Jr Bischoping,
  SVP, Finance & CFO
• Susan L Bostrom,
  Director
• Timothy E Guertin,
  Director
• Clarence R Verhoef,
  SVP, Finance, Corp Controller
• Venkatraman Thyagarajan,
  Director
• Sunny Sanyal,
  SVP and President, ICB
• Robert H Kluge,
  Corporate Vice President
• Richard M Levy,
  President and CEO
• Ruediger Naumann Etienne,
  Director
• John Seely Brown,
  Director
• Erich R Reinhardt,
  Director
• Tai Yun Chen,
  VP and Corporate Controller
• David W Jr Martin,
  Director
• Steven A Leibel,
  Director
• Kent J Thiry,
  Director
• Allen S Lichter,
  Director
• Samuel Hellman,
  Director
• Crisanto C Raimundo,
  Corporate Controller
• Terry R Lautenbach,
  Director
• Joseph B Phair,
  VP Admin,Gen Counsel,Secretary
• Elisha W Finney,
  Corporate Vice President & CFO
• Kevin O'reilly,
  SVP, President of Oncology Sys